Vanda Pharmaceuticals' motion sickness drug, Nereus, has been approved by the U.S. FDA, marking a significant breakthrough in treatment for motion-induced vomiting. This approval comes after a rigorous evaluation process, including two late-stage studies involving 681 patients, where the drug, tradipitant, demonstrated remarkable efficacy in reducing vomiting. The drug works by blocking a brain receptor associated with nausea and vomiting, offering a promising solution for those susceptible to motion sickness. With sales potential exceeding $100 million annually at peak in the U.S. alone, Nereus is poised to become a game-changer in the pharmaceutical industry. However, it's worth noting that the FDA initially placed a partial clinical hold on tradipitant in 2018, citing the need for additional studies due to the chronic nature of motion sickness. This decision was later reversed, recognizing motion sickness as an acute condition. Vanda Pharmaceuticals acquired tradipitant from Eli Lilly in 2012 and has been exploring its potential in various medical conditions, including motion sickness, gastroparesis, and diabetes-related nausea. While the pricing of Nereus remains undisclosed, its approval signals a new era in motion sickness management, offering hope to those who have long sought effective remedies.
